Fig. 6: Astrocytic Nrf2 slows transcriptional perturbation and physical deterioration of the MAPTP301S mouse. | Nature Communications

Fig. 6: Astrocytic Nrf2 slows transcriptional perturbation and physical deterioration of the MAPTP301S mouse.

From: Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology

Fig. 6

A RNA-seq analysis of the early-stage neocortex (MAPTP301S vs WT). Genes induced (red) and repressed (blue) are highlighted (>1FPKM, Benjamini–Hochberg-adjusted p value (p_adj)<0.05); n = 4 animals per genotype. B RNA-seq analysis of early-stage neocortex (MAPTP301S_X_GFAP-Nrf2 vs. GFAP-Nrf2). Genes induced (red) and repressed (blue) from A  are highlighted; n = 4 animals per genotype. C, D A comparison of the fold change in gene expression caused by MAPTP301S expression in an otherwise WT background (i.e. MAPTP301S vs. WT) compared to the fold change in gene expression caused by MAPTP301S expression against a GFAP-Nrf2 background (i.e. MAPTP301S vs. MAPTP301S_X_GFAP-Nrf2). Genes induced (C) or repressed (D) (i.e., genes highlighted in B) are shown. C Note how GFAP-Nrf2 represses the induction of MAPTP301S -induced genes and inhibits the repression of MAPTP301S -repressed genes. t = 11.12, df = 398, p = 1.7E−25 (C); t = 11.89, df = 458, p = 1.2E−28 (D), paired t-test. E Horizontal bar performance of mice of the indicated genotypes. Mean ± SEM shown (n = 39 WT, 53 MAPTP301S, 17 MAPTP301S_X_GFAP-Nrf2 mice studied at 19 and 20 weeks; 32 WT, 35 MAPTP301S, 17 MAPTP301S_X_GFAP-Nrf2 at 21 weeks). Two-way ANOVA reveals a main genotype effect (F (2, 83) = 23.13, p = 1.04E−8). *Bonferroni’s post-hoc test (left to right): p = 0.0338, 0.00028, 2.93E−11.

Back to article page